Production of monoclonal antibodies for therapeutic purposes: A review

Alejandra, Waller-Pulido; Miriam Irene, Jiménez-Pérez; Fabio Antonio, Gonzalez-Sanchez; Patricia, Rojo-Gutierrez Rocio; Elizabeth, Torres-Anguiano; Aleman-Aguilar, Juan Pablo; Rebeca, Garcia-Varela

doi:10.1016/j.intimp.2023.110376

Cited by 11 publications

(3 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methods of preparation of BsAbs are classified as chemical coupling, hybridoma binding and gene cloning methods (82,83). Chemical cross-linking is the process of forming disulfide bonds between antibody molecules of different specificities or F(ab') by using a specific chemical cross-linking agent, thus creating a heterodimer.…”

Section: Preparation Technology Of Bsabsmentioning

confidence: 99%

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Guo,

Wu,

Xue

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Recent progressions in immunotherapy have transformed cancer treatment, providing a promising strategy that activates the immune system of the patient to find and eliminate cancerous cells. Bispecific antibodies, which engage two separate antigens or one antigen with two distinct epitopes, are of tremendous concern in immunotherapy. The bi-targeting idea enabled by bispecific antibodies (BsAbs) is especially attractive from a medical standpoint since most diseases are complex, involving several receptors, ligands, and signaling pathways. Several research look into the processes in which BsAbs identify different cancer targets such angiogenesis, reproduction, metastasis, and immune regulation. By rerouting cells or altering other pathways, the bispecific proteins perform effector activities in addition to those of natural antibodies. This opens up a wide range of clinical applications and helps patients with resistant tumors respond better to medication. Yet, further study is necessary to identify the best conditions where to use these medications for treating tumor, their appropriate combination partners, and methods to reduce toxicity. In this review, we provide insights into the BsAb format classification based on their composition and symmetry, as well as the delivery mode, focus on the action mechanism of the molecule, and discuss the challenges and future perspectives in BsAb development.

show abstract

Section: Preparation Technology Of Bsabsmentioning

confidence: 99%

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Guo,

Wu,

Xue

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…mAbs have a very important role in immunization, as they have great potential as adjuncts to immune responses when the organism cannot produce them on its own, and confer unique specificity by recognizing and targeting specific antigens. In addition, there are different types of mAbs (murine, chimeric, and humanized) that, when used alone, are also combined with radiation, chemotherapy, and hormone therapy, which enhances their therapeutic properties [115].…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Fundamental Considerations of Targeted Drug Therapies for Breast Cancer

Castillo-Tobías,

Berlanga,

Poblano

et al. 2023

Future Pharmacology

View full text Add to dashboard Cite

Breast cancer is a complex disease for which pharmacological treatment does not guarantee success or cure. In addition, current pharmacological therapies induce unwanted side effects due to their lack of specificity or selectivity. Therefore, it is necessary to develop new therapeutic options to improve these aspects. Currently, phytochemicals with antineoplastic properties have been identified from a wide variety of plant sources, and new therapeutic options have been developed based on the conjugation of drugs with polymeric matrices, resulting in nanoparticles or hydrogels with improved properties. Some antineoplastic drugs have been conjugated with antibodies to improve their selectivity and specificity. One of the most important advances in the treatment of breast cancer has been the development of cyclin inhibitors and gene therapy. This review provides an overview of drugs derived from medicinal plants and polymeric matrices with high potential for use in the treatment of breast cancer. We also highlight the clinical evidence for the use of anti-HER2 monoclonal antibodies and cyclin inhibitors in breast cancer, as well as the advantages of using conjugated antibodies. Finally, we mention some considerations that should be taken into account in the search for new therapeutic agents from phytochemicals, polymers, antibodies, cyclin inhibitors, and gene therapy focused on the treatment of breast cancer.

show abstract

“…The production of recombinant monoclonal antibodies [186] is a well-established process [187,188] that has been extensively described in a number of reviews [188][189][190][191][192]. There are additional thorough reviews on bispecific antibodies [193][194][195], nanobodies [196,197], bi-, tri-and tetrabodies [198], and other derivatives [199,200].…”

Section: Introduction Of Carbonyl Groups With Genetic Engineering Too...mentioning

confidence: 99%

Introduction of Carbonyl Groups into Antibodies

Gulyak,

Alferova,

Korshun

et al. 2023

Molecules

View full text Add to dashboard Cite

Antibodies and their derivatives (scFv, Fabs, etc.) represent a unique class of biomolecules that combine selectivity with the ability to target drug delivery. Currently, one of the most promising endeavors in this field is the development of molecular diagnostic tools and antibody-based therapeutic agents, including antibody–drug conjugates (ADCs). To meet this challenge, it is imperative to advance methods for modifying antibodies. A particularly promising strategy involves the introduction of carbonyl groups into the antibody that are amenable to further modification by biorthogonal reactions, namely aliphatic, aromatic, and α-oxo aldehydes, as well as aliphatic and aryl–alkyl ketones. In this review, we summarize the preparation methods and applications of site-specific antibody conjugates that are synthesized using this approach.

show abstract

Production of monoclonal antibodies for therapeutic purposes: A review

Cited by 11 publications

References 119 publications

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Fundamental Considerations of Targeted Drug Therapies for Breast Cancer

Introduction of Carbonyl Groups into Antibodies

Contact Info

Product

Resources

About